Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Cash & Current Investments: 2019-2024

Historic Cash & Current Investments for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $241.0 million.

  • Fulcrum Therapeutics' Cash & Current Investments rose 176.26% to $200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $882.4 million, marking a year-over-year increase of 102.61%. This contributed to the annual value of $241.0 million for FY2024, which is 2.03% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Cash & Current Investments of $241.0 million as of FY2024, which was up 2.03% from $236.2 million recorded in FY2023.
  • In the past 5 years, Fulcrum Therapeutics' Cash & Current Investments ranged from a high of $241.0 million in FY2024 and a low of $35.1 million during FY2022.
  • Its 3-year average for Cash & Current Investments is $170.8 million, with a median of $236.2 million in 2023.
  • Per our database at Business Quant, Fulcrum Therapeutics' Cash & Current Investments crashed by 41.01% in 2020 and then spiked by 573.03% in 2023.
  • Fulcrum Therapeutics' Cash & Current Investments (Yearly) stood at $57.1 million in 2020, then tumbled by 37.93% to $35.4 million in 2021, then fell by 0.89% to $35.1 million in 2022, then surged by 573.03% to $236.2 million in 2023, then climbed by 2.03% to $241.0 million in 2024.